ESMO 2026 Conference Intelligence

1/4 🔥 #ESMO26 Lung Cancer Presidential Highlights 🇪🇸 Madrid | October 24–25, 2026 Three major Phase 3 lung cancer LBAs, each with potential to reshape treatment paradigms: 🎙️ LBA3 | DeLLphi-305 🎙️ LBA5 | KRASCENDO 1 🎙️ LBA6 | SAFFRON Three Phase 3 readouts to watch closely at #ESMO26 👀 @myESMO @OncoAlert @Larvol

Patrick Forde @FordePatrick

Three lung cancer phase 3 trials selected for presidential sessions at #ESMO26 ! I have been honoured to chair the metastatic lung track this year w 2 proffered paper & 2 rapid oral sessions & even more phase 3 trial results in EGFR lung cancer, radiation, & IO! #lcsm @myESMO https://t.co/h2sHUZf4td

👁 12.6K ❤ 100 🔁 31

Markus Eckstein @Markuseckstein3

Small cell carcinoma of the bladder: why ADC targets from conventional UC do not simply carry over, and what may work instead 🧵 New in @Histo_Journal: 88 SmCCB from Milan and Erlangen, 79 fully profiled by IHC for ASCL1, NEUROD1, POU2F3, YAP1, HNF4α, NE and tuft cell markers, plus 7 therapeutic targets and NECTIN4 FISH. 🔬 Two phenotypes 🟢 High-NE (57/79): ASCL1-driven, NEUROD1-driven or mixed, diffuse synaptophysin, chromogranin and CD56 🟠 Low-NE (22/79): POU2F3-driven, YAP1-driven or TF-negative, weak or absent NE markers, significantly associated with admixed urothelial, glandular or squamous histology 🎯 ADC and BiTE targets, one by one Nectin-4 (membranous) • Completely negative in 75% (60/80) • Median H-score 0, mean 11.6, max 220 • Higher in Low-NE than High-NE (median 1.5 vs 0, P<0.001), consistent with retained urothelial differentiation NECTIN4 amplification (FISH) • 16/73 (21.9%), a frequency comparable to conventional UC • No difference between High-NE and Low-NE (P=0.835) • No association with membranous protein (P=0.099) TROP2 • Completely negative across the cohort HER2, FOLR1, Claudin 18.2 • Rare and weak expression only DLL3 • Positive in 35/43 evaluable High-NE cases (81%) • Nearly absent in Low-NE (P<0.001) • Relevant for DLL3-directed BiTEs such as tarlatamab and for DLL3 ADCs in development SLFN11 • Median H-score 125, significantly higher in High-NE (P=0.006) • Supports testing DNA-damaging strategies in this group 💡 Key takeaways 1️⃣ High-NE SmCCB is largely Nectin-4 protein negative, yet carries NECTIN4 amplifications at rates similar to conventional UC. The amplification is present, the protein is not. 2️⃣ Our hypothesis: this points to NE transdifferentiation from a urothelial precursor that already harboured the amplification. The gene status is retained, while the urothelial protein program, including Nectin-4, is switched off during lineage change. The equal amplification rate in both phenotypes fits this model. It needs confirmation in paired and clonal analyses. 3️⃣ Practical consequence: NECTIN4 FISH alone should not be read as a surrogate for target presence in SmCCB. Gene status and membranous protein both need to be assessed. 4️⃣ Enfortumab vedotin benefit cannot be assumed in High-NE SmCCB. Low-NE tumours with residual urothelial features remain the more plausible candidates for UC-type ADCs. 5️⃣ High-NE SmCCB behaves biologically like SCLC: DLL3-high, SLFN11-high. This makes it a rational population for SCLC-directed strategies. 6️⃣ A tuft cell-like subset exists: POU2F3-driven tumours co-express POU2AF2 (11/16) and ChAT (13/16), with preclinical mSWI/SNF vulnerabilities. 7️⃣ A simple workflow (NE markers ± TF panel) can stratify SmCCB in routine diagnostics today. ⚠️ Limits: retrospective, TMA-based, no treatment or outcome annotation. Treatment-annotated and paired pre/post-therapy cohorts are the next step. Big shout out to Nazario Tenace from San Raffaele he drove this work as fellow. Bright future for this talented pathologist. Shout out also at great collaborators from Sann Raffaele @AndreaNecchi @Albert0Briganti @F_Montorsi and @mauriziocollechia @maurilioponzoni @claudiodoglioni and @UroMoschini Great collaboration between San Raffaele Milan and UK Erlangen, led by Nazario Tenace, with @andreanecchi 🔗 https://t.co/JEgkOU7a24

👁 5.6K ❤ 43 🔁 24

2 wks to #ESMO26! Here’s a📝of🔑studies for GeneralOnc that could change/reinforce SoC: - #INTerpath001 - #VOLGA - #ANZUP1801 - #LITESPARK011 - #DeLLphi305 - #SAFFRON - #CLARITYGastric01 - #MOIO - #TroFuse005 - Breast Ca Updates #OncTwitter @myESMO @OncoAlert https://t.co/9uGw605Q0W

My Top 10 Lung Cancer Abstracts #ESMO26 👇 https://t.co/lbGT7HzRNN

👁 4.1K ❤ 68 🔁 23

Aya Mohamed | MSc, MD 🎗 @Dr_Oncologista

OptiTROP-Lung05: 🫁 A strong phase 3 signal for ADC + immunotherapy in 1L PD-L1+ advanced NSCLC. Sac-TMT + pembrolizumab vs pembrolizumab: • PFS: NR vs 5.7 months; HR 0.35 • ORR: 70.2% vs 42.0% https://t.co/XDvBtfRXXA @OncoAlert #lcsm #LungCancer https://t.co/heBozvKuxF

👁 4.1K ❤ 63 🔁 12

Clinical Trials17 trials with discussion

DeLLphi-305 Tarlatamab + durvalumab vs durvalumab · 1L maintenance ES-SCLC (Phase 3 — interim OS met; LBA3, investigational combo) Full trial profile →

28.1K imp · 8 tweets ▼

🚀 ESMO 2026 | 16 ABSTRACTS TO WATCH — THE QUESiTIONS THAT COULD CHANGE ONCOLOGY! From personalized cancer vaccines to next-generation ADCs, bispecific antibodies and targeted therapies — ESMO 2026 promises important clinical answers. 🔬 PART 01 | PRESIDENTIAL SPOTLIGHT INTerpath-001 • VOLGA • DeLLphi-305 • DASL-HiCaP Cancer vaccines, perioperative bladder therapy, DLL3 targeting and prostate cancer intensification. 🫁 PART 02 | LUNG & GI BREAKTHROUGHS KRAScendo 1 • SAFFRON • CLARITY-Gastric 01 • HARMONi-GI1 KRAS G12C inhibition, EGFR/MET resistance, CLDN18.2 ADCs and PD-1/VEGF bispecifics. 🎗️ PART 03 | BREAST CANCER: THE NEXT QUESTIONS FINER • VIKTORIA-1 • TALENT • NATALEE Endocrine resistance, AKT/PI3K pathway targeting, early HER2-low ADCs and long-term survival. 🧬 PART 04 | NEW ADCs & IMMUNOTHERAPY PANKU-Breast01 • KEYNOTE-B49 • OptiTROP-Lung04 • SigVie-002 Bispecific ADCs, immunotherapy in HR+ breast cancer, TROP2 and integrin β6 targeting. 💡 16 studies. 16 clinical questions. One congress. Which results will truly change practice? The data will decide. 📚 References: ESMO Congress 2026 Scientific Programme; official trial protocols and sponsor announcements. #ESMO2026 #ESMO #MVOnco #Oncology #ClinicalTrials #LateBreakingAbstracts #PrecisionOncology #Immunotherapy #CancerVaccines #ADC #BispecificAntibodies #LungCancer #BreastCancer #BladderCancer #ProstateCancer #Melanoma

Tom Newsom-Davis @tnewsomdavis

Countdown to #ESMO26 DeLLphi-305: ES-SCLC ⏰ Saturday Presidential Session 1 💉 1L maintenance Tarlatamab + Durvalumab 🚨 We know from Press Release that this is positive for ORR, PFS & OS 🤔 Likely to be (one) of the standards of care where funded ❓Where do B7-H3 ADCs fit in ❓Would 1L ADC & immunotherapy, then Tarlatamab 2L be better ❓Or will DeLLphi-305 show Tarlatamab in 1L maintenance is best place for it 🧐 Much to consider

👁 1.9K ❤ 20 🔁 7

🆙 #ESMO26 #LCSM Presidential Symposium 🔥DeLLphi-305: Tarlatamab Plus Durvalumab vs Durvalumab as 1L Maintenance Therapy Following Durva, Platinum, and Etoposide in Extensive-Stage Small Cell Lung Cancer 🎙️ @sands_jacob 🔢LBA3 🎯Met Primary Endpoint: Tarlatamab+Durvalumab Significantly Improved OS, PFS, and ORR vs Durvalumab Alone ☑️NCT06211036 🔗 https://t.co/Lb6tzuMm0z @OncoAlert @Larvol @myESMO @IASLC

👁 1.5K ❤ 8 🔁 2

MeDucation @MeDucationai

@OncBrothers @myESMO @OncoAlert @shilpaonc @apolo_andrea @RManochakian @GlopesMd @YJanjigianMD @DrSapnaPatel @shimoi_oncology @dr_yakupergun @SuyogCancer @sands_jacob Great list!! DeLLphi-305 is the one we'd circle for general oncologists, since tarlatamab plus durvalumab in first-line ES-SCLC would bring CRS monitoring into frontline practice. Our OncoPulse tool helps you keep up to date with latest research drops.

👁 106 ❤ 3 🔁 0

John Silver @JohnGolf_CA

@tnewsomdavis Great post - thanks for laying out the options. Sequencing bispecifics vs ADCs in SCLC is going to be the big debate 🧐 My bet: if DeLLphi-305 shows a clean OS benefit in maintenance, hard to argue against 1L tarlatamab #ESMO26

👁 96 ❤ 1 🔁 0

Esk @esenthil84

📡 𝟭𝟵/𝟭𝟵 — 𝗧𝗛𝗘 𝗪𝗔𝗧𝗖𝗛-𝗟𝗜𝗦𝗧 ━━━━━━━━━━━━━━ ESMO Congress: Madrid, 23–27 October 2026. The supplied watch-list includes: INTerpath001 • VOLGA • ANZUP1801 • DeLLphi305 • SAFFRON • CLARITYGastric01 • MOIO • TroFuse005. These remain watch-list items here; no unverified results are being assigned to them. 🔵 Carotuximab + apalutamide: A phase II programme is confirmed. The circulated 17.7-vs-2.0-month PFS figure needs the complete primary dataset, denominators, confidence intervals and comparator context before clinical interpretation. 🤖 AI in oncology: An “augment, not replace” spotlight supplies no comparative clinical-outcome evidence. 𝗥𝗲𝗮𝗱𝗶𝗻𝗴 𝗿𝘂𝗹𝗲: Population → comparator → absolute benefit → toxicity → maturity → affordability. #OncoTwitter #Oncology #PrecisionOncology #Immunotherapy #BreastCancer #ColonCancer #Myeloma #CLL #RCC #ESMO26

👁 52 ❤ 0 🔁 0

KRASCENDO-1 Divarasib vs sotorasib/adagrasib · Previously treated KRAS G12C+ NSCLC (Phase 3 — topline PFS+OS met; LBA5) Full trial profile →

21.7K imp · 6 tweets ▼

🆙 #ESMO26 #LCSM Presidential Symposium 🔥Krascendo 1: Efficacy and Safety of Divarasib vs Sotorasib or Adagrasib in Previously Treated Locally Advanced or Metastatic KRAS G12C-Mutated NSCLC 🎙️ @FSkoulidis 🔢LBA5 🎯Met Primary and Key Secondary Endpoints: Divarasib Significantly Improved PFS and OS vs Sotorasib/Adagrasib ☑️NCT06497556 🔗 https://t.co/bIUj6lELxQ @OncoAlert @Larvol @myESMO @IASLC @KRASKickers

👁 1.3K ❤ 12 🔁 4

Tom Newsom-Davis @tnewsomdavis

Lots of lung data to look forward to at #ESMO26 We already know from press release that Krascendo-1 ➡️ significant PFS & OS benefit Details needed, of course, but next gen KRASi with greater activity than modest benefit of current options is very welcome #LCSM https://t.co/emfCzkvXeA

👁 1.0K ❤ 9 🔁 3

OncLive.com @OncLive

🤔 "All patients who were response evaluable and had at least one post-baseline scan exhibited tumor shrinkage," said Ferdinandos Skoulidis, MD, PhD, MRCP, of @UTMDAnderson on first-line efficacy data for divarasib plus pembrolizumab in KRAS G12C+ NSCLC from the KRASCENDO-170 study Full video ➡️: https://t.co/gz82FRq1wv #oncology

👁 154 ❤ 1 🔁 1

#ESMO26 @myESMO @AstraZeneca Three Presidential Symposium wins headed to Madrid: HUTCHMED/AZ SAFFRON beats chemo after osimertinib resistance, Roche's divarasib beats sotorasib/adagrasib in KRAS G12C NSCLC, and AZ VOLGA =durva to bladder cancer. Watch: https://t.co/WiCRrBxsIN

👁 25 ❤ 1 🔁 0

SAFFRON Savolitinib + osimertinib vs platinum-pemetrexed · MET-driven EGFRm NSCLC post-osimertinib (Phase 3 — topline PFS+OS positive; LBA6) Full trial profile →

21.5K imp · 6 tweets ▼

🧬 The NDA for savolitinib plus osimertinib in MET-driven, EGFR-mutated NSCLC is in at the FDA. The phase 3 SAFFRON trial hit on both PFS and OS vs platinum-based chemotherapy after osimertinib progression. Full data due at #ESMO26 👇 #lcsm https://t.co/yixx0WiBIK

OncLive.com @OncLive

👁 1.7K ❤ 6 🔁 0

🆙 #ESMO26 #LCSM Presidential Symposium 🔥SAFFRON: Osimertinib + Savolitinib vs Platinum–Pemetrexed in EGFRm MET-Overexpressed and/or -Amplified Advanced NSCLC Post-Osi 🎙️Dr. Shun Lu 🔢LBA6 🎯Met Primary (PFS) and Key Secondary (OS) Endpoints ☑️NCT05261399 🔗 https://t.co/bIUj6lELxQ @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters

👁 1.6K ❤ 8 🔁 2

d.planchard @dplanchard

So many new options coming post Osi-Chemo! Super exciting times ahead for discussions, especially with the SAFFRON results (#EGFR MET+ #ESMO26 ) which will have its place whether 1L is Osi alone or Osi + Chemo! 💥@StephenVLiu https://t.co/rHZfRYrLss

👁 1.4K ❤ 11 🔁 3

Philipp Doc @GamerPhilDoc

@dplanchard @StephenVLiu Agreed, the post-osimertinib space is getting crowded in the best way. Curious how SAFFRON will shape sequencing, especially after 1L Osi + chemo. #ESMO26

👁 51 ❤ 1 🔁 0

Guru P. Sonpavde, MD @sonpavde

👁 25 ❤ 1 🔁 0

OptiTROP-Lung06 Sacituzumab tirumotecan (sac-TMT) + pembrolizumab vs chemo + pembrolizumab · 1L PD-L1-negative advanced non-squamous NSCLC (Phase 3 — met primary PFS with a positive OS trend; NCT06711900; LBA66; investigational)

14.2K imp · 3 tweets ▼

New #bladdercancer #clinicaltrial opening now: Bladder-preservation for muscle-invasive #bladdercancer (MIBC) - #TroFuse055 is a Phase III clinical trial that evaluates the value of neoadjuvant sacituzumab tirumotecan (Sac-TMT) + MK3475A followed by consolidation MK3475A when combined with conventional chemoradiotherapy - this trial builds upon the value that chemoradiation brings to patients with MIBC who have elected to avoid radical cystectomy surgery - 1) Sac-TMT is a Trop2 binding antibody drug conjugate (ADC) conjugated to a potent topoisomerase-1 inhibitor payload (belotecan) and 2) MK3475A is subcutaneous pembrolizumab - Trial is opening globally and sponsored by @Merck - we are pleased to offer at our institution @AdventHealthCFL Cancer Institute Orlando, #Florida - Please note @BladderCancerUS @FLASCO_ORG @tompowles1 @DrYukselUrun @drenriquegrande @AndreaNecchi @shilpaonc - https://t.co/Y3Ie8osa7V

👁 6.3K ❤ 45 🔁 9

Aya Mohamed | MSc, MD 🎗 @Dr_Oncologista

👁 4.1K ❤ 63 🔁 12

🆙 #ESMO26 Proffered Paper I: #LCSM Mets 🔥OptiTROP-Lung06: Sacituzumab Tirumotecan (Sac-TMT) Plus Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Treatment for PD-L1 Negative Advanced Non-Squamous NSCLC 🎙️Dr. Caicun Zhou 🔢LBA66 🎯Met Primary Endpoint: Sac-TMT+Pembrolizumab Significantly Improved PFS vs Chemo+Pembrolizumab, With Positive OS Trend ☑️NCT06711900 🔗 https://t.co/uGHKJfjhvW @OncoAlert @Larvol @myESMO @IASLC

👁 3.8K ❤ 26 🔁 7

SigVie-002 Sigvotatug vedotin vs docetaxel · Previously treated non-squamous NSCLC (Phase 3 — missed primary OS endpoint in the overall population; NCT06012435; LBA68; investigational) Full trial profile →

4.5K imp · 3 tweets ▼

🆙 #ESMO26 Proffered Paper I: #LCSM Mets 🔥SigVie-002: Phase 3 Study of Sigvotatug Vedotin vs Docetaxel in Previously Treated Nonsquamous Non-Small Cell Lung Cancer 🎙️ @peters_solange 🔢LBA68 🎯Missed Primary OS Endpoint in Overall Population ☑️NCT06012435 🔗 https://t.co/uGHKJfjhvW @OncoAlert @Larvol @myESMO @IASLC

👁 2.0K ❤ 12 🔁 2

#ESMO26 @myESMO #melsm INTerpath-001, SigVie-002 and HARMONi-GI1 are all scheduled for the Oct 24-25 weekend in Madrid. https://t.co/ZhPcqDnm0q

👁 7 ❤ 1 🔁 0

OptiTROP-Lung04 Sacituzumab tirumotecan (sac-TMT) vs platinum chemo · EGFR-mutated NSCLC after EGFR-TKI progression, final OS analysis (Phase 3 — NCT05870319; LBA67; investigational)

4.3K imp · 2 tweets ▼

🆙 #ESMO26 Proffered Paper I: #LCSM Mets 🔥OptiTROP-Lung04: Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) Versus Platinum-Based Chemotherapy in EGFR-Mutated NSCLC After Progression on EGFR-TKI 🎙️Dr. Li Zhang 🔢LBA67 ☑️NCT05870319 🔗 https://t.co/uGHKJfjhvW @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters

👁 1.9K ❤ 13 🔁 9

DeLLphi-304 Tarlatamab · Previously treated SCLC — extended OS follow-up (Phase 3 — median OS 13.6 vs 8.3 mo, HR 0.60; NCT05740566; Abstract 3808O; ✅ FDA-approved 2L+ ES-SCLC) Full trial profile →

3.8K imp · 4 tweets ▼

🆙 #ESMO26 #LCSM Proffered Paper Session 🔥DeLLphi-304: Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 Trial 🎙️ @charlesrudin 🔢3808O 🎯Primary Analysis: Median OS 13.6 vs 8.3mo (HR 0.60) ☑️NCT05740566 🔗 https://t.co/grEfaUchKN @OncoAlert @Larvol @myESMO @IASLC

👁 2.8K ❤ 15 🔁 5

FJ ⭐️⭐️+⭐️ @pistoto2017

In my humble opinion, and looking at the hospital real world I believe that the most logical sequence would be: IMforte: Atezo + Lurbinectedin in 1lm; Tarlatamab: 2l . Until there are more viable options, this strikes me as the most plausible approach. #SCLC #lungcancer #ESMO26

👁 858 ❤ 11 🔁 3

MeDucation @MeDucationai

👁 106 ❤ 3 🔁 0

Oct 26 PM 14:45 (21:45) LBA64 Neotorch final analysis (perioperative toripalimab); KEYNOTE-671 biomarker analysis; DeLLphi-304 extended follow-up 16:30 (23:30) Perioperative strategies in oncogene-driven resectable NSCLC (Stephanie Saw)

Tom Newsom-Davis @tnewsomdavis

SARON Consolidation radiotherapy vs standard of care · Synchronous oligometastatic NSCLC (Phase 3 RCT — NCT02417662; Abstract 2613O; investigational)

1.9K imp · 2 tweets ▼

Impressive RWE. Congratulations 👏 🚨 High-impact prospective NSCLC data coming at #ESMO26 🚨 SARON: a randomised-controlled trial of consolidation radiotherapy for synchronous oligometastatic NSCLC Proffered Paper 1: NSCLC Metastatic Sun 25 Oct @fifimcdrmh https://t.co/KdBpbb8SiV

👁 1.2K ❤ 5 🔁 3

🆙 #ESMO26 Proffered Paper I: #LCSM Mets 🔥SARON: A Randomised-Controlled Trial of Consolidation Radiotherapy for Synchronous Oligometastatic Non-Small Cell Lung Cancer 🎙️Dr. Fiona McDonald 🔢2613O ☑️NCT02417662 🔗 https://t.co/iyD9xWSAFb @OncoAlert @Larvol @myESMO @IASLC

👁 715 ❤ 5 🔁 0

NeoTORCH Toripalimab + chemo (perioperative) vs chemo alone · Resectable Stage II–III NSCLC (Phase 3 — final analysis met EFS and MPR; NCT04158440; LBA64; investigational)

1.8K imp · 2 tweets ▼

🆙 #ESMO26 Proffered Paper: #LCSM Non-Mets NSCLC, others 🔥NEOTORCH: Toripalimab Plus Chemotherapy as Perioperative Treatment for Resectable Stage II or III Non-Small Cell Lung Cancer 🎙️Dr. Shun Lu 🔢LBA64 🎯Final Analysis Met Primary Endpoints: EFS and MPR in Stage II-III Population ☑️NCT04158440 🔗 https://t.co/grEfaUbJVf @OncoAlert @Larvol @myESMO @IASLC

👁 1.8K ❤ 8 🔁 5

PERSEE (GFPC 01-2020) Pembrolizumab ± platinum chemo · 1L advanced NSCLC, PD-L1 ≥50% (Phase 3 — NCT04547504; Abstract 2614O; investigational)

1.6K imp · 2 tweets ▼

🆙 #ESMO26 Proffered Paper I: #LCSM Mets 🔥PERSEE (GFPC 01-2020): Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%, Phase 3 Trial 🎙️ @decroisette 🔢2614O ☑️NCT04547504 🔗 https://t.co/uGHKJfjhvW @OncoAlert @Larvol @myESMO @IASLC

👁 1.5K ❤ 14 🔁 3

chantal decroisette @decroisette

Very honored to present the results of the PERSEE phase III trial (GFPC 01-2020) in an oral session at #ESMO26 in Madrid 🇪🇸 📅 Sunday, October 25 🕙 10:15 AM 🎤 Abstract 2614O https://t.co/HBW9zbnUh9 Thank you to the investigators, the GFPC, Brest CHU and Centre Leon Bérard !

👁 86 ❤ 7 🔁 6

KEYNOTE-671 Perioperative pembrolizumab + neoadjuvant chemo · Early-stage resectable NSCLC — biomarker/efficacy analysis at ESMO26 (Phase 3 — ✅ FDA-approved regimen since Oct 2023; NCT03425643; Abstract 2519O) Full trial profile →

1.4K imp · 2 tweets ▼

🆙 #ESMO26 Proffered Paper: #LCSM Non-Mets NSCLC, others 🔥Association of Biomarkers With Efficacy in the Phase 3 KEYNOTE-671 Study of Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy in Early-Stage Non–Small-Cell Lung Cancer 🎙️ @marinagarassino 🔢2519O ☑️NCT03425643 🔗 https://t.co/grEfaUchKN @OncoAlert @Larvol @myESMO @IASLC

👁 1.4K ❤ 5 🔁 0

PANKU-Lung01 Izalontamab brengitecan (Iza-Bren) · EGFR-mutant non-squamous NSCLC after progression on a 3rd-generation EGFR TKI (Phase 3 — met primary PFS at interim analysis; NCT06382116; LBA71; investigational) Full trial profile →

1.3K imp · 2 tweets ▼

🆙 #ESMO26 Proffered Paper II: #LCSM Mets 🔥PANKU-Lung01: Randomized Phase III Study of Izalontamab Brengitecan (Iza-Bren) in EGFR-Mutant Non-Squamous NSCLC After Progression on a Third Generation EGFR TKI 🎙️Dr. Li Zhang 🔢LBA71 🎯Met Primary PFS Endpoint at Interim Analysis ☑️NCT06382116 🔗 https://t.co/M4ccE0iSMW @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters

👁 1.3K ❤ 6 🔁 2

Oct 26 AM 08:30 (15:30) LBA69 SANOVO; LBA71 PANKU-Lung01; LBA72 HERON-Lung01 (post EGFR-TKI) 10:15 (17:15) Thymic tumours: THRIVE (rivoceranib), iTHYM (ivonescimab); LBA62 MDT-BRIDGE (neoadjuvant ctDNA clearance)

SANOVO Savolitinib or placebo + osimertinib · Treatment-naive EGFR-mutated NSCLC with MET overexpression (Phase 3 — met primary PFS in high-MET and ITT populations; NCT05009836; LBA69; investigational)

1.0K imp · 2 tweets ▼

🆙 #ESMO26 Proffered Paper II: #LCSM Mets 🔥SANOVO: Savolitinib or Placebo Combined With Osimertinib in Treatment-Naïve Advanced NSCLC With EGFR Mutation and MET Overexpression: Results From the Phase 3 Study 🎙️Dr. Yi-Long Wu @ThomasW35874311 🔢LBA69 🎯Met Primary PFS Endpoint in Both High-MET and ITT Populations ☑️NCT05009836 🔗 https://t.co/M4ccE0iSMW @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters

👁 1.0K ❤ 6 🔁 2

ASTRIDE Serplulimab or atezolizumab + chemo · Extensive-stage SCLC, US patients (Phase 3 — NCT05468489; Abstract 3809O; investigational)

1.0K imp · 1 tweet ▼

🆙 #ESMO26 Proffered Paper: #LCSM Non-Mets NSCLC, others 🔥ASTRIDE: Randomized Trial of Serplulimab or Atezolizumab Plus Chemotherapy in USA Patients With Extensive-Stage Small Cell Lung Cancer 🎙️ @drgandara 🔢3809O 🔗 https://t.co/grEfaUchKN ☑️NCT05468489 @OncoAlert @Larvol @myESMO @IASLC

👁 1.0K ❤ 7 🔁 0

HERON-Lung01 Ruzaltatug rezetecan (HER3-directed ADC) vs platinum chemo · EGFR-mutated advanced NSCLC after EGFR-TKI progression (Phase 3 — met primary PFS by BICR at interim analysis; NCT06671379; LBA72; investigational)

647 imp · 2 tweets ▼

🆙 #ESMO26 Proffered Paper II: #LCSM Mets 🔥HERON-Lung01: Ruzaltatug Rezetecan, a HER3-Directed ADC, vs Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC Progressing After EGFR-TKI 🎙️Dr. Yi-Long Wu @ThomasW35874311 🔢LBA72 🎯Met Primary Endpoint at Interim Analysis: Statistically Significant PFS Improvement by BICR vs Chemo ☑️NCT06671379 🔗 https://t.co/M4ccE0ikXo @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters

👁 643 ❤ 4 🔁 0

Veli Bakalov, MD @HemeOncBuddy

HARMONi-2 Ivonescimab (AK112, PD-1/VEGF bispecific) vs pembrolizumab · 1L PD-L1-positive advanced NSCLC (Phase 3, NCT05499390, Akeso; WCLC26 OS update; investigational in US)

188 imp · 2 tweets ▼

7️⃣ Transplant + what's new 👉 GVL is therapeutic; DLI works best in CML. 👉 TIGIT: tiragolumab NEGATIVE (SKYSCRAPER-01/02/06). 👉 Ivonescimab (PD-1xVEGF) beat pembro in PD-L1+ NSCLC (HARMONi-2, HR 0.51). 👉 V940 mRNA vaccine + pembro: melanoma RFS HR 0.56 (KEYNOTE-942).

👁 95 ❤ 1 🔁 0

OncoNexus @Onco_Nexus

@TejasPatilMD reviews HARMONi-2 data from #WCLC 2026 for #ivonescimab vs #pembrolizumab in NSCLC. Overall survival favored ivonescimab, with the clearest benefit in patients with PD-L1 ≥50%. Global data will help define its role in frontline treatment. Watch Dr. Patil put these findings into context: https://t.co/yLNhEE79nA @CUCancerCenter

👁 93 ❤ 1 🔁 0

SKYSCRAPER-01 Tiragolumab + atezolizumab vs placebo + atezolizumab · 1L PD-L1-high NSCLC (Phase 3, NCT04294810, Roche)

95 imp · 1 tweet ▼

Veli Bakalov, MD @HemeOncBuddy

👁 95 ❤ 1 🔁 0

🎗️Breast Cancer13 tweets captured

Paolo Tarantino @PTarantinoMD

As per tradition, here are my hand picked top 10 breast cancer abstracts to keep an eye on at #ESMO26. Key words: ADCs, CDK4, IO, and impactful updates of practice-changing phase 3 trials. See you in Madrid! 🇪🇸 #ESMOAmbassadors https://t.co/ik7DY3WXva

👁 16.7K ❤ 184 🔁 54

There is no breast cancer or colorectal cancer study in the ESMO 2026 Presidential Symposia🧐 I also struggle to see why DASL-HiCaP and VOLGA were given Presidential slots. In high-risk nonmetastatic prostate cancer, STAMPEDE already showed an overall survival benefit from adding abiraterone to androgen deprivation therapy. DASL-HiCaP may provide useful data for patients receiving salvage radiotherapy, but it does not compare darolutamide with abiraterone. In cisplatin-ineligible muscle-invasive bladder cancer, VOLGA tests perioperative enfortumab vedotin plus durvalumab against cystectomy-based standard care. Enfortumab vedotin plus pembrolizumab has since shown a survival benefit and received FDA approval, yet VOLGA does not compare the two regimens. Both trials addressed real gaps when they were designed. Today, the lack of a comparison with the relevant active treatment makes their impact on treatment choice much less clear. I don’t feel particularly qualified to comment on genitourinary cancers, but I genuinely don’t understand why these two studies were selected for Presidential Symposia.

👁 9.4K ❤ 35 🔁 7

Kristina Jankovic, MD @JankovicK

The @OncoAlert🚨Newsletter brings you the latest in oncology 📰 Giredestrant + everolimus in ER+/HER2− ABC FDA: belzutifan + lenvatinib approved in ccRCC; Priority Review for durva + EV in MIBC (VOLGA) MCED screening RCT Subscribe👉https://t.co/Q2y6eL3OIq and stay informed! https://t.co/SeHfVHGL2W

👁 1.3K ❤ 8 🔁 5

Mali Barbi, MD MSc | Breast & Gyn Oncologist @DrBarbiOnc

Following #ESMO26 from afar this year, but following closely. Three questions I'm bringing to it in gyn onc: Endometrial: are we starting to treat it like breast cancer? #TroFuse005 (sac-TMT, TROP2 ADC, Presidential Symposium, Oct 26) after platinum and IO, OS and PFS met. Plus sac-TMT + pembro in post-platinum pMMR EC (phase 2). Molecular groups driving treatment, ADCs. We are slowly getting there. Ovarian: Here ADCs are everywhere, and still no answer for ADC after ADC. The PROC readout I'm watching is #DENALI (azenosertib, WEE1i, OS, Oct 23), with phase 3 ASPENOVA in cyclin E1+ disease behind it. Not an ADC. Maybe that's the most clinically relevant point. Cervical: did we find a better way to prevent it? My biggest agenda, and I haven't seen a prevention abstract on the program yet. We have the vaccine and screening. What we don't have is reach. Going to be a busy October. Follow along. #gyncsm

👁 630 ❤ 7 🔁 2

ipharmacenter @ipharmacenter

The #EC approved #Enhertu + pertuzumab as 1L therapy for HER2+ metastatic #breastcancer, the first new 1L regimen in the EU in a decade. https://t.co/aD4lffkpY8 #Oncology #Cancer #ESMO26 #OncoAlert

👁 41 ❤ 0 🔁 0

OncoAlert @OncoAlert

This week’s OncoAlert 🚨 Newsletter is OUT! Packed with the latest updates in oncology. subscribe here 👉 https://t.co/NhtuRoIyO3 This week's must-reads: 🔸 Spotlight: Giredestrant + everolimus in ER+/HER2− ABC, PFS HR 0.38 in ESR1m (NEJM) 🔸 FDA: belzutifan + lenvatinib approved in ccRCC; Priority Review for durva + EV in MIBC (VOLGA) 🔸 MCED screening RCT in 142K adults: no drop in stage III/IV (NEJM) 🔸 Plus Lung, GU, GI, Breast Pinging: @OncoAlert @Uromigos @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @JaniceTNBCmets @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @sonpavde @drenriquegrande @tompowles1 @cdanicas @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @FernandoOnco @ElisaAgostinett @to_be_elizabeth @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @BenWestphalen @CentralParkWMD @graokane @amanda

👁 7.5K ❤ 36 🔁 15

🔵GI Cancers10 tweets captured

Erman Akkus @Erman_Akkus

🚀Upper GI oral abstracts of #ESMO26 👇 ✅Gastric/esophageal ✅Pancreatic ✅Hepatobiliary ✅NET/NEC #cancer #oncology #MedX #GI #pancreatic #biliary #cholangiocarcinoma #liver #hepatocellular #gastric #esophageal #neuroendocrine @OncoAlert https://t.co/VF3ifn5SPD

👁 7.1K ❤ 96 🔁 51

Hong Jae Chon @hongjaechon

🚨 Great news from the @myESMO Scientific Committee! 👉 #6777 Our Phase 1 study of BGB-B2033 (#GPC3 x 4-1BB bispecific) in advanced #HCC has been selected for a Proffered Paper oral presentation at #ESMO26. Join us for the unveiling of our dose optimization and escalation data. #LiverX 🗓️ Sat, Oct 24 | 10:15-11:45 📌 FPN: 1679O

👁 1.2K ❤ 21 🔁 6

Lorenza Rimassa @LorenzaRimassa

Proud and honored to be an #ESMOAmbassador! Please follow me during #ESMO26 in Madrid for novel data on #HCC #CCA #BTC #PDAC #livercancers #HPBcancers @myESMO @HUNIMED @HumanitasMilano https://t.co/gOVp2EznVE

👁 695 ❤ 18 🔁 3

Jose Tapia @TapiaJC1

My picks for #CRC and #PDAC sessions at #ESMO26 Madrid. Some interesting posters as well. Full abstracts will be released soon. Looking forward to meeting with colleagues and discussing these data. @myESMO #colorectal #pancreas #colon #rectum @OncoAlert https://t.co/5LiMCi7L3c

👁 128 ❤ 5 🔁 0

#ESMO26 @myESMO @Incyte Incyte brings an oral KRAS G12D inhibitor to colorectal + pancreatic cancer, plus CDK2/bevacizumab data in Cyclin E1-high ovarian cancer. Akeso's cadonilimab spans 15 presentations across 10+ tumor types. Madrid, Oct 23-27. Watch: https://t.co/7CBpziLZue

👁 26 ❤ 1 🔁 0

PRIME-ROSE @PRIMEROSE_EU

PRIME-ROSE community will showcase at #ESMO26 how cross-border collaboration can accelerate evidence generation for patients with limited treatment options Poster 827 on Sun 25 Oct 12-13 Pertuzumab and Trastuzumab in HER2/ERBB2 amp treatment-refractory met colorectal cancer https://t.co/I6s8ARzYcv

👁 14 ❤ 0 🔁 0

Clinical Trials2 trials with discussion

CLARITY-Gastric01 AZD0901 (claudin 18.2 ADC) vs investigator's choice · 2L+ advanced gastric/GEJ cancer (Phase 3, NCT06346392, AstraZeneca; investigational)

9.4K imp · 5 tweets ▼

OncoDaily GI @OncoDailyGI

10 Gastroesophageal Cancer Trials to Watch at ESMO 2026 ESMO 2026 will feature several key readouts across gastric, gastroesophageal junction, and esophageal cancers. Trials to watch: • HERIZON-GEA-01 — zanidatamab + chemotherapy ± tislelizumab in 1L HER2-positive advanced GEA • KC-WISE — anbenitamab + chemotherapy in previously treated HER2-positive gastric/GEJ cancer • LOMAC — 4 vs 6 months of adjuvant XELOX in stage II–IIIB gastric cancer • G-HOPE-001 — arcotatug tavatecan vs investigator’s choice in previously treated CLDN18.2-positive gastric/GEJ cancer • KEYNOTE-975 — pembrolizumab + definitive chemoradiotherapy in esophageal/GEJ cancer • TQB2102 + bemotrizumab ± capecitabine in 1L HER2-positive advanced gastric/GEJ cancer • GERCOR-GONO DEWI — dostarlimab with a watch-and-wait strategy in localized dMMR/MSI-H GEA • CLARITY-Gastric 01 — sonesitatug vedotin in previously treated CLDN18.2-positive gastroesophageal cancer • FORTITUDE-101/102 — bemarituzumab efficacy by FGFR2 amplification status • IKFs602/AIO RAMIRIS — FOLFIRI + ramucirumab vs paclitaxel + ramucirumab after prior taxane therapy @KoheiShitara @MDmanishshah @WainbergZev 👉 https://t.co/0hEuAwsZst #ESMO2026 #GastricCancer #GIOncology

👁 867 ❤ 17 🔁 7

Daisuke Kotani, MD, Ph.D 小谷大輔 @DaisukeKotani

#ESMO26 | Presidential symposium My featured abstracts ▪️ LBA1: Individualized mRNA neoantigen therapy + pembrolizumab in stage IIB–IV melanoma ➡️Positive results already announced (press release) ▪️ LBA7: Sone-Ve in 2L+ CLDN18.2+ GEC (CLARITY-Gastric 01) ➡️Positive results already announced (press release) ▪️ LBA8: Ivonescimab + chemo vs durvalumab + chemo in 1L BTC (HARMONi-GI1) ➡️Positive results already announced (press release) ▪️ LBA10: MOIO: Noninferiority trial of reduced-frequency IO in responding patients @myESMO @OncoAlert

👁 766 ❤ 8 🔁 3

Esk @esenthil84

👁 52 ❤ 0 🔁 0

HARMONi-GI1 Ivonescimab + chemo vs durvalumab + chemo · 1L advanced biliary tract cancer (Phase 3 — interim OS met; LBA8, Presidential)

8.4K imp · 7 tweets ▼

Yannick Buccella MD @YannickBuccella

One study I’m watching at this month’s European cancer meeting: HARMONi-GI1. Can a new drug called ivonescimab + chemo help people with advanced bile duct cancer live longer than a treatment we already use (chemo + classic immunotherapy)? What’s different about ivonescimab? It’s designed to help our immune system fight cancer AND block signals tumors use to grow new blood vessels. Two jobs, one drug. That’s great, but only matters if patients actually benefit. The company already said it was successful. Let’s talk numbers, and with what side effects. A meaningful gain could change which drug we give with chemo. We need the full results, including how well they apply beyond China, before calling it a revolution. It already beat pembrolizumab in lung cancer, beating durvalumab in bile duct cancer would be the next step. We know more on October 25th.

👁 2.1K ❤ 24 🔁 2

OncoDaily GI @OncoDailyGI

9 Hepatobiliary Cancer Trials to Watch at ESMO 2026 The ESMO Congress 2026 will feature several important readouts across hepatocellular carcinoma and biliary tract cancers, spanning TACE-based strategies, adjuvant therapy, first-line immunotherapy, DDR-selected maintenance treatment, bispecific antibodies, and CAR-T cell therapy. Trials to watch: • EMERALD-3 — Liver function trajectories and post-progression outcomes with STRIDE ± lenvatinib + TACE in embolization-eligible HCC • BGB-B2033 — Dose optimization and updated dose-escalation data with the GPC3 × 4-1BB bispecific antibody in advanced HCC • LEAP-012 — Long-term overall survival with lenvatinib + pembrolizumab + TACE in unresectable, non-metastatic HCC • C-CAR031 — Updated phase I results with GPC3-targeted armored CAR-T therapy in advanced HCC • HARMONi-GI1 — Ivonescimab + gemcitabine-cisplatin versus durvalumab + gemcitabine-cisplatin as first-line treatment for advanced biliary tract cancer • COMPANION-002 — Paclitaxel ± tovecimig in previously treated advanced biliary tract cancer • ACTICCA-1 — Adjuvant gemcitabine + cisplatin versus standard of care after curative-intent resection of cholangiocarcinoma and gallbladder carcinoma • OPTIMUM — Maintenance olaparib ± durvalumab in DDR gene-mutated advanced biliary tract cancer • Envafolimab + GEMOX — First-line envafolimab + GEMOX versus GEMOX alone in advanced biliary tract cancer Together, these presentations will provide new data across locoregional and advanced HCC, as well as adjuvant, maintenance, first-line, and previously treated biliary tract cancer settings. @hongjaechon @changhoon_yoo @oncodaily @myESMO https://t.co/aHafYF96sL #ESMO2026 #HCC #GIOncology #OncoDaily

👁 1.4K ❤ 18 🔁 11

Summit Therapeutics @SMMT_TX

HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at #ESMO26 https://t.co/BQempU8KOZ

👁 912 ❤ 18 🔁 4

Daisuke Kotani, MD, Ph.D 小谷大輔 @DaisukeKotani

👁 766 ❤ 8 🔁 3

MedShr @medshronline

ESMO 2026 is 2 weeks away - Madrid, 23–27 October. Our predicted ESMO 2026 Top 10 Trials includes: 🧬 INTerpath-001: mRNA vaccine + pembro, melanoma ⏱ MOIO: 3-monthly immunotherapy 🎯 HARMONi-GI1: PD-1 × VEGF, biliary Which new data will change practice? #ESMO26 #Oncology https://t.co/OnOU7ZB8p3

👁 727 ❤ 3 🔁 0

#ESMO26 @myESMO #melsm INTerpath-001, SigVie-002 and HARMONi-GI1 are all scheduled for the Oct 24-25 weekend in Madrid. https://t.co/ZhPcqDnm0q

👁 7 ❤ 1 🔁 0

🔷GU Cancers91 tweets captured

TROFUSE-055 is a randomized phase 3 non-muscle invasive bladder cancer trial. It’s another trial exploring bladder surgery sparing approaches. This study tests the combination of SAC-TMT with Pembro (68% RR in advanced disease) followed by chemoradiation. The control is ChemoRT (+/- NAC). This study is distinct from EV309 where no chemoRT is given in the study arm. We will need many trials to identify the optimal approach. The role of chemoRT in ADC driven cCR is unknown. @OncoAlert

👁 16.0K ❤ 81 🔁 40

Markus Eckstein @Markuseckstein3

Our NECTIN4 scoring system for predicting enfortumab vedotin response in urothelial carcinoma is just published. 🔬 The short version: NECTIN4 is not a failed biomarker. It has been measured in the wrong compartment. 📊 179 EV-treated mUC patients, multicenter, FISH plus IHC, benchmarked against EV-301 EPAR data. Why the field thought NECTIN4 was ubiquitous 🧠 In EV-301 the median H-score was 250, with 82.6% ≥150. That near-universal expression underpinned the biomarker-unselected label. In our cohort, membranous H-score alone was 160. Cytoplasmic was 200. Combined, 260, with 78.2% ≥150, almost exactly mirroring EV-301. So the trial numbers most likely reflect membranous plus cytoplasmic staining. That single methodological choice is why NECTIN4 looked like it was everywhere. 🎯 And it matters, because only one compartment predicts anything: ✅ Membranous 2+/3+ vs 0/1+: ORR 55.1% vs 25.5% (p<0.001), mPFS 7.1 vs 2.9 months (HR 0.45), mOS 12.3 vs 6.9 months (HR 0.57). ❌ Cytoplasmic: ORR 49.6% vs 39.5% (p=0.4). No PFS or OS signal. ❌ Bulk NECTIN4 mRNA, which cannot resolve localisation: no association either. Adding cytoplasmic staining inflates positivity and dilutes prediction. Negativity rate drops from 12% to 3.4%. More positives, less information. 📉 The scoring system 🔬 Four tiers (0, 1+, 2+, 3+) adapted from the ASCO/CAP HER2 gastric algorithm, chosen deliberately because it accounts for incomplete membranous staining, the same framework that carried T-DXd to tumour-agnostic approval. Blinded interobserver testing, 44 cases, three raters, two with no prior NECTIN4 experience: 📈 Fleiss' κ 0.749 across all four tiers. 📈 Fleiss' κ 0.874 for the clinically relevant 0/1+ vs 2+/3+ cutoff. Almost perfect agreement. Reproducible, teachable in a short training session, deployable in routine practice. Genomics on top 🧬 NECTIN4 amplification in 25.1% (45/179). ORR 76.2% vs 36.6%. mPFS 12.2 vs 3.9 months (HR 0.40). mOS 30.1 vs 8.5 months (HR 0.33). At 24 months, 58.8% of amplified patients were alive versus 19.0%. And IHC prescreens for it: 80% of amplified tumours are 3+, under 5% of 0/1+ tumours carry an amplification. Restricting FISH to 2+/3+ captures 97.8% of amplified cases while sparing 29.1% of patients any molecular testing. ⚡ The integrated three-tier model: 1️⃣ Amplified: ORR 76.2%, mOS 30.1 mo 2️⃣ Non-amplified, membranous high: ORR 42.9%, mOS 8.8 mo 3️⃣ Non-amplified, membranous low: ORR 26.1%, mOS 6.9 mo Both remained independent in multivariable models. C-index for OS improves from 0.557 to 0.621 when amplification and membranous expression are combined. Neither marker alone does what the two do together. Where I think this lands 🎯 I do not (!) read this as an argument for testing every patient . With EV+P as first-line standard and few alternatives, a negative result rarely changes what you do today and shouldn't change it right now given the high EVP efficacy. But that is an argument about the therapeutic landscape, not about the biology. And the landscape is changing fast: HER2 ADCs, TROP2, HER3/EGFR, NECTIN4 radioligands and T-cell engagers. The moment two viable options compete for the same patient, the question stops being "does the target matter" and becomes "which target first." Notably, unlike the HER2-low paradigm, EV-301 showed an attenuated treatment effect in NECTIN4-low disease, PFS HR around 0.9 with confidence intervals crossing 1 (check out Figure 1 of the paper). ⚠️Prospective validation is running: EVOKE (DRKS00034745). Immense thanks to @niklas_kluemper and Jonas Saal, to Thomas Büttner, Sebastian Rauch and Fabienne Lange, and to every centre and biobank that contributed. This was a genuinely collaborative effort within the fantastic GUARDIANS and BRIDGE Consortium. 🙏 🔗 https://t.co/CuQR9LJe6k @Uroweb @AmerUrological @ASCO @PathSoc @OncoAlert @Histo_Journal @andreanecchi @emanuele_crupi @danieleraggi83 @raffcolo @Dr_Aggen @DrRosenbergMSK @h_alahmadie @PGrivasMDPhD @shilpaonc @drenriquegrande @amerseburger @brookmans76 @DrYukselUrun @onkowissen @imedverse @UroDocAsh @urotoday @EUplatinum @JCO_ASCO @CCR_AACR @niklas_kluemper @DrRosenbergMSK @Dr_Aggen @Uromigos @tompowles1 @shilpaonc @PGrivasMDPhD #Uropathology #urothelial #BladderCancer #NECTIN4 #pathtwitter

👁 15.0K ❤ 81 🔁 27

Enrique Grande @drenriquegrande

What great news!!!!! 👏👏👏👏👏👏👏 Perioperative Durvalumab plus EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial. @OncoAlert @seom @CANVES_ES @GUOncologyNow @OncBrothers @myESMO https://t.co/uOS52u6l7V

👁 8.0K ❤ 100 🔁 35

Shilpa Gupta @shilpaonc

Looking forward to @tompowles1 presenting the VOLGA trial at @myESMO Presidential Session on Sat, Oct 24! Congrats Tom, on yet another practice changing work in urothelial cancer! This trial will address several important questions about optimal dosing of EV-IO and need for adjuvant EV. @Uromigos @LosUromigos @uromigosjapan @brian_rini @QMBCI @scocmem @OncoAlert @DrChoueiri @montypal @PGrivasMDPhD @apolo_andrea @MattGalsky @UroDocAsh @IBCG_BladderCA @AstraZeneca @drenriquegrande @Annals_Oncology @TomFlaigMD @DrRosenbergMSK @AndreaNecchi @FAndreMD

👁 6.4K ❤ 71 🔁 12

Guru P. Sonpavde, MD @sonpavde

👁 6.3K ❤ 45 🔁 9

European Urology Oncology @EurUrolOncol

🌄 Monday Morning Mention! ✍ BRIEF REPORT: Gemcitabine-Cisplatin Chemotherapy Induces Nectin-4 Downregulation and Enfortumab Vedotin Resistance in Bladder Cancer by Christoph Nössing...Bernhard Englinger et al 💡 Link to full article: https://t.co/FsSsPVIoaM 👏 Thank you to the authors for trusting EUO to publish your work! @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @DaveDandrea @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

👁 5.3K ❤ 42 🔁 18

Clinical Trials7 trials with discussion

VOLGA Perioperative durvalumab ± tremelimumab + neoadjuvant enfortumab vedotin · Muscle-invasive bladder cancer (Phase 3; LBA2, Presidential) Full trial profile →

51.2K imp · 23 tweets ▼

FDA grants Priority Review for the VOLGA trail, in which 3 neoadjuvant cycles of EV and a year of Perioperative durvalumab was given for patients with muscle invasive bladder cancer. Press release states an EFS and OS advantage. Data will be presented #ESMO26 @OncoAlert @myESMO @Annals_Oncology https://t.co/xviPkTWjhN

👁 13.2K ❤ 132 🔁 61

Enrique Grande @drenriquegrande

👁 9.4K ❤ 35 🔁 7

👁 8.0K ❤ 100 🔁 35

OncoAlert @OncoAlert

👁 7.5K ❤ 36 🔁 15

Petros Grivas @PGrivasMDPhD

Congrats @tompowles1 et al. Looking forward to data & discussion reconciling VOLGA, ctDNA data from peri-operative MIBC trials with EVP, etc. @myESMO #ESMO26 #ESMOAmbassadors @Uromigos @OncoAlert @GPentheroudakis @DrRosenbergMSK @MonikaJoshimd @shilpaonc @OncBrothers @fredhutch https://t.co/H2elS4aNz0

👁 3.3K ❤ 39 🔁 9

Really looking forward to the Presidential presentation of Phase 3 VOLGA @myESMO #ESMO26 Congrats to Tom @tompowles1 on another major UC presentation: Tom´s presidential sequence itself reflects how rapidly the field has evolved since 2023: EV-302 → NIAGARA → IMvigor011 → now VOLGA — from metastatic disease toward perioperative treatment and biomarker-guided strategies! EV-303 vs VOLGA raises one of the most important questions in perioperative MIBC: how much EV do we actually need? EV-303 established perioperative EV+pembrolizumab as a highly effective regimen, with EFS HR 0.40 and OS HR 0.50 versus radical cystectomy alone. VOLGA takes a different approach: 3 cycles of neoadjuvant EV + durvalumab ± tremelimumab, followed by surgery and adjuvant immunotherapy — without further EV. The positive topline results already show significant EFS benefit for both experimental strategies and significant OS benefit for EV+durvalumab So a key question for me will be: If the efficacy benchmarks are similar, do all patients really need adjuvant EV? This matters because EV toxicity is cumulative. The exposure–neuropathy relationship is striking, with higher EV exposure associated with earlier grade ≥2 peripheral neuropathy. Interestingly, even in EV-303, only 67% of patients undergoing cystectomy started adjuvant therapy, already raising questions about the relative contributions of the pre- and postoperative components. Perhaps the next evolution is not simply more perioperative therapy, but response-adapted therapy: Who needs adjuvant EV — and who has already received enough before surgery? pCR, ctDNA/MRD and molecular biomarkers may ultimately help us answer this. Looking forward to VOLGA and seeing you in Madrid! 🎯 @OncoAlert @weoncologists @Uromigos @DrChoueiri @drenriquegrande @DrYukselUrun @UroDocAsh @urotoday @Markuseckstein3 @PTarantinoMD @raffcolo @amerseburger @Dr_Aggen @apolo_andrea @apolo_andrea

👁 2.6K ❤ 43 🔁 14

Kristina Jankovic, MD @JankovicK

👁 1.3K ❤ 8 🔁 5

Shilpa Gupta @shilpaonc

Congrats @tompowles1 and entire VOLGA team! Having another perioperative EV-IO option without adjuvant EV addresses an important question of adequate doses of EV. Looking forward to the data! @uromigosjapan @Uromigos @TresUramigas @brian_rini @PGrivasMDPhD https://t.co/A4OrLr9d23

👁 1.1K ❤ 11 🔁 6

OncLive.com @OncLive

💥 @FDA has granted priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data, reinforcing the potential of durvalumab. Read more here 📈: https://t.co/DZWQ4DC9u3 #blcsm #oncology

👁 1.1K ❤ 0 🔁 0

Oncology Tube @oncologytube

VIDEO: ESMO Oct 23–27 Madrid — which Top 10 LBAs for US clinics? 🇸 https://t.co/4zqOT4u04I ✅ #1 INTerpath-001 melanoma RFS+DMFS met (LBA1) #2 VOLGA MIBC — EFS+OS improved; FDA Priority Review ✅ HRs/medians embargoed Countdown #10→#1. #ESMO2026 #LBA #Oncology https://t.co/GZ2npxHn0t

👁 789 ❤ 4 🔁 0

Daniel Castellano @cdanicas

Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial https://t.co/OJAOBIxFrI

👁 772 ❤ 14 🔁 4

Bijoy Telivala @BijoyTelivala

Volga vs EV 303 in bladder cancer Good to see trials reducing EV exposure Both for Cisplatin ineligible If both of their HR etc look same Will people be ok not using post op EV ? Interesting time for Bladder ca @RenoHemonc - using your pic @OncBrothers @SuyogCancer https://t.co/SRxqXStcfu

👁 557 ❤ 3 🔁 1

Top GU Oncology Updates – August–September 2026 The past eight weeks brought major updates across prostate, bladder, and kidney cancer, including phase 3 publications, regulatory actions, new radiation oncology guidance, and long-term randomized data. Key findings • PSMAddition showed improved radiographic progression-free survival with [177Lu]Lu-PSMA-617 added to ADT plus an ARPI in PSMA-positive mHSPC. • LITESPARK-011 demonstrated longer PFS with belzutifan plus lenvatinib versus cabozantinib after prior PD-1/PD-L1 therapy in advanced ccRCC. • VOLGA moved into FDA Priority Review after perioperative durvalumab plus neoadjuvant enfortumab vedotin improved event-free and overall survival in patients with MIBC who were ineligible for or declined cisplatin. • BOND-003 reported durable complete responses with intravesical cretostimogene in BCG-unresponsive NMIBC with carcinoma in situ. • ASTRO issued its first clinical practice guideline dedicated to radiation therapy for bladder cancer. • Eight-year PACE-A data showed high long-term disease control with both SBRT and prostatectomy, with important differences in patient-reported function. • NRG-GU005 found no superiority in urinary quality of life or disease-free survival with five-fraction SBRT versus moderately hypofractionated IMRT. • STEEL showed a progression-free survival signal with enzalutamide intensification during salvage radiotherapy in high-risk biochemical recurrence. • CHMP issued a positive opinion for perioperative enfortumab vedotin plus pembrolizumab in resectable MIBC. • 68Ga-NYM096 received FDA Breakthrough Therapy and Fast Track designations for CAIX-targeted PET imaging in ccRCC. Takeaway: These updates reflect the continued movement of established therapies into earlier disease settings while highlighting the growing importance of imaging, toxicity monitoring, radiation expertise, and multidisciplinary care across GU Oncology. Highlighted by Ahmed M. Elalfy, MD, PhD https://t.co/E0munIE6XG #GUOncology #OncoDaily

👁 300 ❤ 13 🔁 3

@US_FDA grants Priority Review to durvalumab + enfortumab vedotin for muscle-invasive bladder cancer. The Phase III VOLGA trial (NCT04960709) showed improved event-free survival and overall survival with this perioperative combination in patients unable to receive cisplatin-based chemotherapy. https://t.co/94juOWoVKT @AstraZeneca

👁 276 ❤ 4 🔁 0

Kohji Takemura, MD @KohjiToncol

The ESMO 2026 LBA titles are now out. Two GU studies will be presented in the Presidential Symposium—and VOLGA is the one to watch! #ESMO26 https://t.co/CYUYWig4xj

👁 243 ❤ 3 🔁 0

Álvaro Pinto @dralvaropinto

👁 157 ❤ 2 🔁 1

Urbano Anido @urbano_anido

VOLGA (company-reported): perioperative durvalumab + enfortumab vedotin improved EFS and OS vs cystectomy alone in cisplatin-ineligible MIBC (n=695). FDA priority review, decision expected Q4 2026. Full data pending; not approved. #BladderCancer #GUsm

👁 152 ❤ 0 🔁 0

Martín Angel @Martin_AngelMD

👁 125 ❤ 0 🔁 0

Dr. Robert @robt_heartdoc

@amerseburger @myESMO @OncoAlert @high5md @Uroweb @ProfHadaschik @DrChoueiri @tompowles1 @OncoBellmunt @DrRosenbergMSK @drenriquegrande @AndreaNecchi @neerajaiims @montypal @Albert0Briganti Great summary. The perioperative wave in MIBC is striking, VOLGA and KEYNOTE-866 back to back. Will be interesting to see if either resets the standard. Kudos for pulling this together.

👁 98 ❤ 1 🔁 0

Onu Anda @ACFER20

ACF Desk Line Healthcare - AstraZeneca's VOLGA results have reached US Priority Review for a defined cisplatin-ineligible bladder-cancer group. The next valuation tests are the full survival data, Q4 FDA decision and eventual patient access. https://t.co/r9axTIfpD1

👁 76 ❤ 0 🔁 0

Patricia Pat @canozoonosity

The VOLGA and KEYNOTE-866 block is the one I'm blocking off. Perioperative triplet data in MIBC has been pending a while. Ten trials, zero translational abstracts, no complaints from me. https://t.co/D8TNCqJ6aX

👁 67 ❤ 0 🔁 0

Michiel Strijbos @StrijbosMichiel

The press release from AstraZeneca reads 'Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial'. So probably yes....

👁 63 ❤ 1 🔁 0

👁 25 ❤ 1 🔁 0

TroFuse-055 Sacituzumab tirumotecan (sac-TMT) + pembrolizumab then chemoradiation vs chemoradiation · Bladder-sparing, non-muscle-invasive/MIBC setting per CT.gov (Phase 3, NCT07829783, Merck)

22.3K imp · 2 tweets ▼

Guru P. Sonpavde, MD @sonpavde

👁 16.0K ❤ 81 🔁 40

👁 6.3K ❤ 45 🔁 9

KEYNOTE-905 / EV-303 Perioperative pembrolizumab ± enfortumab vedotin + cystectomy vs cystectomy alone · Cisplatin-ineligible MIBC (Phase 3, NCT03924895, Merck)

11.5K imp · 7 tweets ▼

3 randomised trials #ESMO26 in muscle invasive bladder cancer. VOLGA = Neoadjuvant EV plus perioperative durvalumab. How will it compare to perioperative EVP (B15/905) where longer periods of EV were given (OS HR = 0.5-0.6). Also, 2 trials (ENERGIZE/KN866) of cisplatin based neoadjuvant chemotherapy with or without PD-1 inhibition (nivolumab or pembrolizumab) . Will they reproduce NIAGARA with OS HR of 0.75 or will we see antagonism with platinum chemo as in metastatic disease . @OncoAlert

👁 5.0K ❤ 82 🔁 24

Andrea Necchi, MD, FASCO @AndreaNecchi

👁 2.6K ❤ 43 🔁 14

What is the performance of neoadjuvant pembro in #PURE01 vs periop EVP #KEYNOTE905 in pts with MIBC? Are this data replicable in a multicentric setting? Waiting for a post-hoc analysis of KN905 to be presented at #ESMO26 @myESMO Indirect comparison of reconstructed individual patient data from KEYNOTE905 and PURE01 @SanRaffaeleMI @MyUniSR @ESMO_Open https://t.co/93iF56d6pO

👁 1.7K ❤ 27 🔁 8

An important detail I overlooked in my earlier post: in VOLGA, EV is limited to three neoadjuvant cycles, with durvalumab ± treme continuing in the adjuvant setting. KN-905 uses nine cycles of EV in total. Substantially lower EV exposure could reduce toxicity and treatment burden. This strategy, with its shorter duration of EV treatment, makes VOLGA’s Presidential slot more understandable. Still, I would have liked to see a breast cancer trial in the Presidential Symposia too 😊 #ESMO26

👁 1.2K ❤ 5 🔁 1

Bijoy Telivala @BijoyTelivala

👁 557 ❤ 3 🔁 1

10 Bladder and Urothelial Cancer Studies to Watch at ESMO 2026 The ESMO Congress 2026 will bring several important updates across urothelial cancer, with a major focus on perioperative treatment for muscle-invasive bladder cancer, alongside new analyses in NMIBC, metastatic urothelial cancer, and UTUC. Studies to watch: • KEYNOTE-866 — Perioperative pembrolizumab + cisplatin/gemcitabine in cisplatin-eligible MIBC • ENERGIZE — Neoadjuvant chemotherapy ± nivolumab in MIBC • KEYNOTE-905/EV-303 — Perioperative pembrolizumab or EV + pembrolizumab in patients with MIBC who are ineligible for or decline cisplatin • KEYNOTE-B15/EV-304 — ctDNA analysis of perioperative EV + pembrolizumab • KEYNOTE-B15/EV-304 — Health-related quality of life with perioperative EV + pembrolizumab • NIAGARA — Molecular subtypes and their association with treatment outcomes in MIBC • GDFather-NEO — Final pathological and radiological outcomes and initial EFS with nivolumab ± visugromab • POTOMAC — Early recurrence and cystectomy-free survival with durvalumab + BCG in papillary-only high-risk NMIBC • TROPHY-U-01 Cohort 7 — SG + EV + zimberelimab in treatment-naïve metastatic urothelial cancer • WUTSUP-02 — Neoadjuvant tislelizumab + disitamab vedotin in high-risk UTUC Together, these presentations will provide new data across muscle-invasive, non-muscle-invasive, metastatic, and upper tract urothelial cancer settings. @AndreaNecchi @oncodaily https://t.co/4bxG5x2lyl #ESMO2026 #BladderCancer #GUOncology #OncoDaily

Wenchang Yue @WenchangYue

For bladder cancer, doing chemotherapy before removing the bladder, isn't that a delay? No, and for the right patients it's the standard approach. Neoadjuvant cisplatin-based combination chemotherapy improves overall survival, with a 5-year absolute improvement of 8% (evidence level 1a). The 2026 edition goes further and makes chemotherapy plus immunotherapy a strong recommendation: cisplatin-eligible patients get cisplatin/gemcitabine plus durvalumab (NIAGARA: two-year overall survival 82.2% versus 75.2%), and cisplatin-ineligible patients get enfortumab vedotin plus pembrolizumab (EV-303: overall survival HR 0.50, pathologic complete response rate 57.1% versus 8.6%). Neoadjuvant chemotherapy also doesn't make the surgery harder. In the Nordic pooled trial, 86% of the treatment arm and 87% of the control arm completed cystectomy, almost the same rate, and a large multicenter retrospective analysis likewise showed no increase in postoperative complication risk with neoadjuvant chemotherapy. One thing to be honest about: for people who don't respond to chemotherapy, these few months really are a net loss. Data from the US National Cancer Database show that patients still above pT2 after neoadjuvant chemotherapy have a higher risk of death (HR 1.46). But the guideline adds: no prospective trial has shown that surgery delayed by neoadjuvant chemotherapy harms survival. #BladderCancer #Oncology #PatientEducation

👁 32 ❤ 0 🔁 0

KEYNOTE-B15 / EV-304 Perioperative enfortumab vedotin + pembrolizumab vs neoadjuvant gemcitabine-cisplatin · Cisplatin-eligible muscle-invasive bladder cancer (Phase 3, NCT04700124, Merck)

9.0K imp · 8 tweets ▼

Bladder cancer highlights for #ESMO26 . 4 randomised phase III studies in perioperative disease. VOLGA (EVD vs EVDT vs cystectomy; KN866 (GC+/-pembro) ENERGIZE (GC+/- nivo); KN905 (pembro vs cystectomy). Also, ctDNA data for EVP vs chemo in B15/EV304. No personalized cancer vaccine or RT +/- ICI data. In advanced disease: Long term data for Rll of EV vs EVP. More data with SAC-TMT/PD1. Also triplet data with EV/SG/PD1. No new breakthrough ADC or data on VEGF/PD1 bispecifics. @Annals_Oncology @myESMO @OncoAlert

👁 5.9K ❤ 96 🔁 39

Karine Tawagi MD @DrKarineTawagi

Highlighting upcoming #ESMO26 GU schedule in Madrid 📆 & looking forward to: 1) BLADDER: -TROPHY-U01 SG + EV/ZIM in 1L mUC -ctDNA from EV304 -LBA VOLGA: peri-op durva/EV +/- treme (➕ press release for EFS & OS) 2) RARE GU: -NAT toripalimab in penile CA -Claudin-6 ADC in GCT https://t.co/zz0jlCDKUy

👁 814 ❤ 15 🔁 6

Wish Dhillon, MD @drwishdhillon

Grateful for the chance to chair the Genitourinary Cancer session at Binaytara’s 2026 Tucson Annual Conference on Advances in Hematology & Oncology. Thank you to Dr. Neda Hashemi (Prostate Cancer), Dr. Irbaz Riaz (Bladder Cancer), and Dr. Alejandro Recio-Boiles (Kidney cancer) for excellent presentations. A few takeaways and ongoing conversations with colleagues: Bladder — already changing practice. KEYNOTE-B15 / EV-304 showed that perioperative enfortumab vedotin plus pembrolizumab improved event-free survival versus neoadjuvant gemcitabine-cisplatin (HR 0.53; median not reached versus 48.5 months), improved overall survival (HR 0.65), and raised pathologic complete response from 32.5% to 55.8% in cisplatin-eligible MIBC. This trial was clearly the highlight of the session! Prostate — TALAPRO-3 and the case for universal NGS. TALAPRO-3 supported early talazoparib plus enzalutamide in HRR-altered metastatic castration-sensitive disease (rPFS HR ~0.48; clearer benefit in BRCA). The practical implication is bigger than one regimen: if biomarker-directed intensification starts at diagnosis of metastatic disease, all patients with metastatic prostate cancer should get next-generation sequencing then — germline and tumor/ctDNA — not late in the course. Prostate Cancer— two debates, not settled algorithms. PSMA-based triplet. PSMAddition added Lu-PSMA-617 to ADT + ARPI in PSMA-positive mCSPC and improved radiographic PFS (HR 0.72), with overall survival still maturing. How that sits next to chemotherapy triplets such as ARASENS (mature OS HR 0.68) is an open question. No head-to-head comparison so far. Perioperative therapy. PROTEUS showed perioperative apalutamide + ADT with radical prostatectomy can deepen pathologic response and improve metastasis-free survival. Whether this becomes routine perioperative care — for whom, for how long, and how it translates to radiation-managed high-risk disease — is still being worked out in real practice and guidelines. Kidney Cancer— intensifying adjuvant care carefully. LITESPARK-022 found adjuvant belzutifan plus pembrolizumab improved DFS versus pembrolizumab alone (HR 0.72; 24-month DFS 80.7% versus 73.7%), with higher grade ≥3 toxicity and immature OS. Another place where careful clinical judgment will help us choose the best regimen for individual patients. @binaytara @IrbazRiaz

👁 806 ❤ 5 🔁 3

Great overview of the GU highlights at #ESMO26 — thanks Toni @DrChoueiri for putting this together! 👏 For me, perioperative MIBC will be one of the key themes in Madrid #ESMO26 @myESMO 🔬 VOLGA — full data on perioperative EV + durvalumab ± tremelimumab, importantly without adjuvant EV, in cisplatin-ineligble MIBC. 🔬 KEYNOTE-866 and ENERGIZE — important data on perioperative immunotherapy strategies in cisplatin-eligible MIBC. Together with NIAGARA and EV-304/ KEYNOTE-B15, this should give us a much clearer picture of perioperative IO strategies in cisplatin-eligible disease — while EV-303/KEYNOTE-905 and VOLGA are reshaping the cisplatin-ineligible setting. The field is rapidly moving from “does perioperative systemic therapy work?” toward which regimen, how much therapy, and for whom? And this is where biomarkers will become increasingly important. Our work supports membranous NECTIN4 expression and NECTIN4 amplification as complementary biomarkers of EV benefit @CCR_AACR & independent data from Galsky et al. link higher tumor NECTIN4 RNA expression with better outcomes on EV+P @EUplatinum Looking forward to seeing the data! @OncoAlert @weoncologists @MattGalsky @urotoday

👁 655 ❤ 5 🔁 4

Urbano Anido @urbano_anido

1/ CHMP gave a positive opinion for perioperative enfortumab vedotin + pembrolizumab in resectable MIBC (EV-304/KEYNOTE-B15, cisplatin-eligible): EFS HR 0.53, OS HR 0.65. European Commission decision pending; not yet EU-approved. #BladderCancer #MIBC

👁 172 ❤ 0 🔁 0

MeDucation @MeDucationai

CHMP backed perioperative enfortumab vedotin + pembrolizumab in resectable MIBC, now regardless of cisplatin eligibility. KEYNOTE-B15, n=808 cisplatin-eligible: 24-mo EFS 79.4% vs 66.2%, HR 0.53. #HemOnc https://t.co/ZEdueKEW6o

👁 94 ❤ 1 🔁 0

OncoNexus @Onco_Nexus

The EMA’s CHMP issued a positive opinion recommending perioperative pembrolizumab plus enfortumab vedotin for resectable MIBC regardless of cisplatin eligibility. In KEYNOTE-B15: • 47% reduction in EFS events • 35% reduction in risk of death • pCR: 55.8% vs 32.5% with chemotherapy Final EC decision expected in Q4 2026. https://t.co/iJoazUr3GJ

👁 92 ❤ 1 🔁 0

KEYNOTE-866 Perioperative pembrolizumab + neoadjuvant gemcitabine-cisplatin vs placebo + chemo · Cisplatin-eligible MIBC (Phase 3, NCT03924856, Merck)

7.2K imp · 5 tweets ▼

👁 5.9K ❤ 96 🔁 39

👁 655 ❤ 5 🔁 4

Dr. Robert @robt_heartdoc

👁 98 ❤ 1 🔁 0

Patricia Pat @canozoonosity

👁 67 ❤ 0 🔁 0

ENERGIZE Gemcitabine-cisplatin ± nivolumab (± BMS-986205) then adjuvant nivolumab · Cisplatin-eligible MIBC (Phase 3, NCT03661320, BMS)

7.0K imp · 3 tweets ▼

👁 5.9K ❤ 96 🔁 39

👁 655 ❤ 5 🔁 4

Karine Tawagi MD @DrKarineTawagi

TROPHY-U-01 Sacituzumab govitecan cohorts (mono; + pembrolizumab; + cisplatin/avelumab) · Unresectable/metastatic urothelial cancer (Phase 2, NCT03547973, Gilead)

1.3K imp · 2 tweets ▼

👁 814 ❤ 15 🔁 6

Here is the company’s description of the mRNA Melanoma cancer therapy. “Along with our partners at Merck, we announced positive results from the Phase 3 INTerpath-001 study of intismeran autogene, our investigational individualized neoantigen therapy” https://t.co/4r0zHw4Fqa

🌑Melanoma12 tweets captured

Zach Lahn @ZachLahn

👁 2.5K ❤ 32 🔁 6

🚀 WHEN ONCOLOGY MOVES WALL STREET! Can a personalized cancer vaccine transform cancer care—and move the stock market? Moderna shares jumped 9.27% in a September 2026 snapshot amid excitement around intismeran autogene (V940) and ESMO 2026. 01 | The Stock-Market Surprise Why did Moderna stock surge? 02 | The Science How does a personalized mRNA vaccine activate tumor-specific T cells? 03 | The First Evidence KEYNOTE-942 Phase IIb: RFS HR 0.51 | DMFS HR 0.41 04 | The Phase III Moment INTerpath-001: RFS and DMFS endpoints met. Detailed results at ESMO 2026, October 24. 💡 The science moved Wall Street. Will the full data justify the excitement? References: Moderna–Merck announcements (2026); KEYNOTE-942; ESMO 2026 programme; MarketChameleon. #MVOnco #ESMO2026 #INTerpath001 #IntismeranAutogene #mRNAVaccine #CancerVaccine #Melanoma #Moderna #Merck #Immunotherapy #Oncology

👁 1.1K ❤ 9 🔁 4

MedShr @medshronline

👁 727 ❤ 3 🔁 0

Jose Fernando Moura, PhD @FernandoOnco

Vaccines 💉 are coming soon to #melanoma #lcsm #pcsm @OncoAlert @oncodaily @larvol @myESMO #ESMO26 https://t.co/KhdWJtdgkS

👁 178 ❤ 1 🔁 0

#ESMO26 @myESMO @Merck Moderna & Merck melanoma vaccine (intismeran autogene + Keytruda) hits RFS/DMFS in Phase 3 INTerpath-001 — first positive Phase 3 for an individualized neoantigen therapy. Presidential Symposium, Madrid Oct 23-27. Watch: https://t.co/Etvx0ea1Vn

👁 74 ❤ 1 🔁 0

Eugene A @lorus77

@unusual_whales "Moderna and its partner Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine (intismeran autogene / mRNA-4157) combined with Keytruda in treating resected melanoma, meeting key survival and recurrence-free endpoints."

👁 63 ❤ 1 🔁 0

Clinical Trials2 trials with discussion

INTerpath-001 Intismeran autogene (mRNA-4157) + pembrolizumab vs pembrolizumab alone · Adjuvant resected Stage IIB–IV melanoma (Phase 3 — topline RFS/DMFS met; first positive Phase 3 for an individualized neoantigen therapy; Presidential Symposium; investigational) Full trial profile →

24.7K imp · 14 tweets ▼

Tempus @TempusAI

Today we announced an expanded collaboration with both @moderna_tx and @Merck to support the potential commercialization of intismeran autogene, a novel individualized neoantigen therapy. Tempus will deliver advanced NGS sequencing and sample collection workflows, combining our clinical infrastructure with mRNA innovation to help bring personalized cancer vaccines to patients at scale. Read on: https://t.co/kSdclhaFFq

👁 12.1K ❤ 90 🔁 13

Oncology Tube @oncologytube

Zach Lahn @ZachLahn

👁 2.5K ❤ 32 🔁 6

👁 789 ❤ 4 🔁 0

MedShr @medshronline

👁 727 ❤ 3 🔁 0

VJ Oncology @VJOncology

At #ASCO26, Matteo Carlino shares 5-year follow-up results from KEYNOTE-942 of intismeran autogene + pembrolizumab vs pembrolizumab alone in resected high-risk #melanoma 💉📊 Watch: https://t.co/mnWO742v7Z #Oncology #MelSM #TrialUpdate #ImmunoOnc @ASCO

👁 414 ❤ 0 🔁 0

90+ abstracts. 20+ cancer types. @Merck heads to ESMO 2026 with new Phase 3 data on mRNA cancer therapy, ADCs, and immunotherapy, including INTerpath-001, TroFuse-005, and KEYNOTE-C93. https://t.co/Nqm4CV41jy https://t.co/KdM9YjPxJd

👁 192 ❤ 2 🔁 0

Pure Monograph @PureMonograph

👁 74 ❤ 1 🔁 0

Eugene A @lorus77

👁 63 ❤ 1 🔁 0

Personalized mRNA cancer vaccines have reached late-stage testing in Europe and beyond. One registered study on https://t.co/MERHOmQUyv pairs intismeran autogene, an individualized mRNA neoantigen therapy, with pembrolizumab in people with high-risk melanoma after surgery. Each patient's vaccine is designed from their own tumour's mutations. The study is now active and no longer recruiting. What makes this approach interesting is the design problem underneath it: picking which tumour mutations to encode, manufacturing a bespoke product per patient, and showing benefit in a properly controlled trial. Results, not headlines, will decide where it goes next. #mRNA #CancerVaccines #Immunotherapy #NovelMedicine

Nature reports Moderna/Merck personalized mRNA vaccine (intismeran autogene) + Keytruda met phase 3 endpoints in 1137 resected high-risk melanoma patients: improved recurrence-free and distant metastasis-free survival vs Keytruda alone. First late-stage mRNA cancer therapy success. It encodes patient-specific tumor neoantigens, separate from COVID mRNA shots. Single case reports of spike protein in metastases remain anecdotal and need more rigorous study.

👁 9 ❤ 0 🔁 0

Chidambara .ML. @chidambara09

RT @ChandrakanthMv: 🚀 ESMO 2026 | LBA1 — A CANCER VACCINE TAKES CENTRE STAGE! INTerpath-001 opens Presidential Symposium I! Can a persona…

👁 — ❤ 0 🔁 1

KEYNOTE-942 Intismeran autogene (mRNA-4157 / V940) + pembrolizumab vs pembrolizumab · Adjuvant resected high-risk stage III/IV melanoma (Phase 2b, NCT03897881, Moderna/Merck; 5-year follow-up ASCO26; Phase 3 = INTerpath-001)

1.7K imp · 3 tweets ▼

Veli Bakalov, MD @HemeOncBuddy

👁 1.1K ❤ 9 🔁 4

VJ Oncology @VJOncology

👁 414 ❤ 0 🔁 0

👁 95 ❤ 1 🔁 0

🎀Gyn Cancers7 tweets captured

Sushil @Sushilberiwal

ESMO 2026 cervical cancer guidelines The INTERLACE is not positioned as routine intensification . It may be considered particularly when access to modern radiotherapy and high-quality IGBT not available @AmericanBrachy @ARRO_org @ASTRO_org @ACROsident @KamravaMD

👁 972 ❤ 14 🔁 5

Thread 2: Cervix and Ovarian 1/5 Part 2 of my #ESMO26 gyn preview: cervical and ovarian cancer, where ADCs keep multiplying and new pathways are emerging 🧵 #gyncsm

👁 850 ❤ 7 🔁 2

Zymeworks Inc. @ZymeworksInc

👁 192 ❤ 2 🔁 0

We’re heading into a busy fall conference season, with Zymeworks researchers presenting new clinical and preclinical data across multiple medical conferences. At #ESMO26 on October 24, we’ll share new clinical results from our Phase 1 randomized dose optimization study of ZW191 in heavily pretreated patients with platinum-resistant ovarian cancer. At #SITC26, we’ll present new preclinical data on a novel approach designed to target IL-7 to tumor-specific T cells. At #PEGSEurope, we’ll showcase work across our next-generation multispecific programs and cytokine engineering. Learn more here: https://t.co/uzYwtNUht0

👁 93 ❤ 2 🔁 0

Clinical Trials6 trials with discussion

TroFuse-005 Sacituzumab tirumotecan (sac-TMT, TROP2 ADC) · Post-platinum/post-IO endometrial cancer — Presidential Symposium, OS and PFS reported met (Oct 26; investigational)

6.1K imp · 4 tweets ▼

Mali Barbi, MD MSc | Breast & Gyn Oncologist @DrBarbiOnc

DENALI (GOG-3066) Azenosertib (WEE1 inhibitor) · Platinum-resistant ovarian cancer (PROC), Part 1b overall survival (abstract 1242RO; investigational)

840 imp · 2 tweets ▼

Mali Barbi, MD MSc | Breast & Gyn Oncologist @DrBarbiOnc

👁 630 ❤ 7 🔁 2

3/5 Ovarian: 2 oral cell cycle agents are of interest. Cyclin E1-driven tumors are common in platinum-resistant disease and have few targeted options. Could this be a new pathway for PROC? 1241RO: INCB123667, a selective CDK2 inhibitor, plus bevacizumab in recurrent ovarian cancer. CDK2 is the direct partner of cyclin E1, making it a logical target in CCNE1-amplified disease. 1242RO DENALI/GOG-3066: overall survival from Part 1b of azenosertib, a WEE1 inhibitor, in PROC. Cyclin E1-high tumors live with high replication stress, and WEE1 inhibition pushes them over the edge.

👁 210 ❤ 2 🔁 0

ZW191 Next-gen FRα-targeted ADC, topoisomerase I payload · Heavily pretreated PROC, randomized dose-optimization (LBA40; sponsor Zymeworks; FDA Fast Track; investigational)

293 imp · 2 tweets ▼

4/5 PROC is now crowded with ADCs, and response rates keep climbing. The questions have shifted: which target, which patient, and at what toxicity cost? FRα beyond mirvetuximab: next-gen FRα ADCs with topoisomerase I payloads. LBA40: randomized dose optimization of ZW191 in heavily pretreated PROC. 1245RO: FONTANA update on torvu-sam in PROC. 1246RO: sofe-M, another FRα ADC, plus bev in platinum-sensitive recurrent ovarian cancer. FRα ADCs are moving earlier. B7-H4 is a newer target in ovarian cancer. In earlier BEHOLD-1 data, Mo-Rez showed a confirmed ORR of 62% at 5.8 mg/kg in PROC. LBA41 brings longer follow-up; 1248RO looks at which biomarkers predict response. 1247RO REJOICE-Ovarian02 cohort B-1: raludotatug deruxtecan, a CDH6 ADC, plus bevacizumab in PROC. How much does bev add to an already active ADC?

👁 200 ❤ 1 🔁 0

Zymeworks Inc. @ZymeworksInc

👁 93 ❤ 2 🔁 0

INCB123667 Oral CDK2 inhibitor + bevacizumab · Recurrent ovarian cancer, CCNE1-amplified disease (Phase 1/2 — abstract 1241RO; sponsor Incyte; investigational)

236 imp · 2 tweets ▼

👁 210 ❤ 2 🔁 0

👁 26 ❤ 1 🔁 0

BEHOLD-1 → BEHOLD-Ovarian01 Mocertatug rezetecan (B7-H4 ADC) · PROC — longer follow-up + biomarker analysis, 62% ORR at 5.8 mg/kg in earlier data (LBA41 + 1248RO; sponsor GSK; Phase 3 BEHOLD-Ovarian01 now enrolling; investigational)

200 imp · 1 tweet ▼

👁 200 ❤ 1 🔁 0

REJOICE-Ovarian02 Raludotatug deruxtecan (CDH6 ADC) + bevacizumab · PROC, cohort B-1 (abstract 1247RO; sponsor Daiichi Sankyo/Merck; investigational)

200 imp · 1 tweet ▼

👁 200 ❤ 1 🔁 0

⬜Other Solid Tumors5 tweets captured